Sage Therapeutics(SAGE) - 2024 Q4 - Earnings Call Presentation

Fourth Quarter and Full Year 2024 Financial Results February 11, 2025 − We may encounter unexpected safety or tolerability issues with respect to any of our product candidates or marketed products; we may encounter different or more severe adverse events at higher doses, different frequency or length of dosing or in new indications. − At any stage, regulatory authorities may ask for additional clinical trials, non-clinical studies or other data in order for us to proceed further in development or to file fo ...